BPC-157: What the Research Shows and Where It Stands Legally

What is BPC-157?

A short chain of amino acids first described by Croatian researchers in 1993.

A peptide is a short chain of amino acids, the building blocks of proteins (see what peptides are). BPC-157 has 15. The name stands for body protection compound 157. Researchers at the University of Zagreb described it in 1993 as a fragment of a larger protein, BPC, found in human gastric juice. What is sold today is made in a lab. The FDA briefing document for the July 2026 advisory meeting lists its chemistry:

• Sequence: GEPPPGKPADDAGLV (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val).
• Formula and weight: C62H98N16O22, about 1,419.5 g/mol as the free base.
• Other names: Bepecin, and PL-14736, its code in early human trials.
• Two forms: The free base (the peptide alone) and the acetate salt are separate ingredients to FDA. Labels often do not say which a vial holds.

You can check the weight of any sequence with the peptide molecular weight calculator.

What does the research on BPC-157 actually show?

Mostly results in rats, plus a handful of small human reports.

Most BPC-157 research is preclinical, meaning done in cells or animals before testing in people. Rodent studies report faster healing of cut tendons, ligaments, muscle, bone and gut lesions. A 2025 systematic review in HSS Journal of orthopedic studies included 36: 35 preclinical and 1 clinical. The authors called the peptide promising but found no clinical safety data.

FDA reviewers noted that no dose-response relationship has been established and its molecular targets are unknown. Proposed mechanisms include more growth factor signaling, less inflammation and angiogenesis, the growth of new blood vessels. These are hypotheses, not proven mechanisms.

Sources: FDA briefing document (May 2026 review) and the 2025 HSS Journal review. Participant counts are as FDA reported them.

What human studies of BPC-157 exist?

Five, all small and short, according to FDA’s literature search.

• Healthy volunteers, rectal enema (24 given BPC-157). A placebo-controlled phase 1 study, reported only in meeting abstracts.
• Ulcerative colitis, rectal enema (53 randomized). A placebo-controlled phase 2 trial, reported as a 2005 abstract. The confidence interval for the difference between groups included zero, and FDA called the data inadequate.
• Knee pain, joint injections (17 identified). A 2021 chart review from one clinic. Some patients also received thymosin beta-4.
• Interstitial cystitis, bladder wall injections (12 women). A 2024 pilot with no comparison group.
• Healthy volunteers, intravenous infusion (2 people). A 2025 safety pilot.

No serious adverse events were reported. FDA said the studies were short, the samples small and safety monitoring mostly unclear. It found no studies in tendonitis and no human pharmacokinetic data (how the body absorbs and clears a drug) for oral, under-the-skin, nasal or skin use.

Why rat results may not hold in people

• Different routes. Many rat studies used injection into the abdomen or drinking water.
• Unknown absorption. How much reaches the blood by the routes people use is unknown.
• Artificial injuries. Lab injuries in healthy animals differ from real sports injuries.

Is BPC-157 safe?

No one knows, because long-term human data do not exist.

FDA concluded there is not enough clinical safety information to describe BPC-157’s safety profile. The gaps are specific:

• No long-term human data. The longest dosing period in published studies was two weeks.
• Short animal studies. In 28-day injection studies, rats and dogs showed changes in clotting times and liver-related signals.
• No cancer studies. FDA found no carcinogenicity studies in animals.
• Immune reactions. Immunogenicity is a tendency to trigger an unwanted immune response. FDA said injected or nasal BPC-157 may pose a significant risk, worsened by clumping and impurities.
• Adverse event reports. FDA’s database held three reports tied to injected BPC-157, including shortness of breath. FDA could not say BPC-157 caused them.

The angiogenesis question

Tumors need new blood vessels to grow. A 2025 literature review in the journal Pharmaceuticals raised a theoretical risk: a substance that promotes vessel growth could, in principle, help an undetected tumor. The Zagreb group that first described BPC-157 disputed this in a published reply. No study has tested it in people.

Is BPC-157 legal in the US?

It is not an approved drug, and its compounding status is undecided.

BPC-157 is not FDA-approved. The route now in debate is compounding, where a licensed pharmacy prepares a medicine for one patient. Under section 503A of the federal drug law, a pharmacy may compound from a bulk ingredient only if it has a USP monograph, is part of an approved drug or is on FDA’s 503A bulks list. BPC-157 meets none of these.

1. 2023. FDA placed BPC-157 in category 2, its list of nominated ingredients that may present significant safety risks.
2. April 2026. After its nominators withdrew, BPC-157 came off category 2. FDA’s category 2 safety-risk page now lists it as nominated but withdrawn, still citing immunogenicity risk.
3. May 2026. FDA staff reviewed it for ulcerative colitis and concluded the criteria weigh against listing it.
4. July 23, 2026. The Pharmacy Compounding Advisory Committee (PCAC), an outside panel, voted 8 to 6 with one abstention to recommend adding it, RAPS reported.
5. As of October 14, 2026. We found no final FDA action. The vote is not binding, and listing requires FDA rulemaking.

What research use only labels mean

Many vials sold online say research use only or not for human consumption. In a 2023 FDA warning letter to a seller of BPC-157 injections and nasal sprays, FDA said the website showed the products were meant for people, making them unapproved new drugs. FDA sent letters with the same reasoning to other peptide sellers as recently as August 2026.

Where does BPC-157 stand in sport and in other countries?

Banned in sport, and unapproved in every country we checked.

The World Anti-Doping Agency’s 2026 Prohibited List names BPC-157 in class S0, non-approved substances, banned at all times. S0 covers drugs no government regulator has approved for human use. The US Anti-Doping Agency’s guide to the 2027 list, effective January 1, 2027, still names BPC-157 under S0.

Regulators: FDA, MHRA, Health Canada, the Therapeutic Goods Administration (TGA) and Medsafe. Status can change, so check with your country’s regulator.

What is actually in a gray-market BPC-157 vial?

Often, no one has checked.

Gray-market products are sold outside the regulated medicine supply, usually online. No regulator tests them before sale. FDA found quality gaps even in the paperwork its two nominators submitted:

• Purity figures alone. Most certificates of analysis (CoAs, a supplier’s test report) FDA found showed only a purity number, not which impurities were present.
• No endotoxin results. Endotoxins are bacterial fragments that can cause fever and shock when injected. The nominators’ CoAs reported no endotoxin or microbe counts.
• Mislabeling. Both nominations named the free base, but the attached CoAs were for the acetate salt.
• Sterility. Medsafe, New Zealand’s regulator, warned in May 2026 that online peptides may contain a different substance than labeled and may not be sterile.

Where does a peptide calculator fit in?

It does arithmetic, not dosing.

BPC-157 has no established human dose, and this site does not suggest one. If a prescriber or study protocol specifies an amount, the math is the same as for any peptide: divide the vial’s mg by the mL of water for the concentration, then divide the amount by the concentration for the volume.

The peptide reconstitution calculator handles single-peptide vials, and the peptide blend calculator handles vials such as BPC-157 with TB-500. To match a result to syringe markings, see how to read an insulin syringe.

Frequently Asked Questions

Sources and References